Moleculin Biotech, Inc. (MBRX) Reaches $1.99 After 6.00% Down Move; Idera Pharmaceuticals Has 1.57 Sentiment

June 19, 2018 - By Peter Erickson

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Logo

Idera Pharmaceuticals Inc (IDRA) investors sentiment decreased to 1.57 in Q1 2018. It’s down -2.32, from 3.89 in 2017Q4. The ratio dived, as 58 investment professionals increased and started new holdings, while 37 reduced and sold their stakes in Idera Pharmaceuticals Inc. The investment professionals in our database now hold: 91.28 million shares, down from 142.24 million shares in 2017Q4. Also, the number of investment professionals holding Idera Pharmaceuticals Inc in top ten holdings was flat from 0 to 0 for the same number . Sold All: 12 Reduced: 25 Increased: 37 New Position: 21.

The stock of Moleculin Biotech, Inc. (NASDAQ:MBRX) is a huge mover today! The stock decreased 4.78% or $0.1 during the last trading session, reaching $1.99. About 146,028 shares traded. Moleculin Biotech, Inc. (NASDAQ:MBRX) has risen 88.76% since June 19, 2017 and is uptrending. It has outperformed by 76.19% the S&P500. Some Historical MBRX News: ; 16/05/2018 – MOLECULIN TO BEGIN CLINICAL TRIALS AT UMC SOUTHWEST CANCER CENTER; 28/03/2018 – Moleculin Biotech, Inc. Reports Financial Results for the Year Ended December 31, 2017; 15/05/2018 – MOLECULIN BIOTECH INC – AS OF MARCH 31, 2018, COMPANY HAD $13.1 MLN IN CASH AND CASH EQUIVALENTS; 24/04/2018 – MOLECULIN BIOTECH INC – ENGAGED BSP PHARMACEUTICALS S.P.A. TO BEGIN PREPARATIONS FOR COMMERCIAL SCALE PRODUCTION OF ANNAMYCIN DRUG PRODUCT; 20/03/2018 Moleculin Announces Grant-Funded Collaboration to Expand Understanding of New Discovery; 24/04/2018 – Moleculin Enters Agreement with BSP Pharmaceuticals for its Leukemia Drug Candidate; 15/05/2018 – MOLECULIN BIOTECH INC- QTRLY SHR LOSS $0.08; 24/05/2018 – Moleculin Invited to Present to International BioForum 2018 Conference; 15/05/2018 – Moleculin Biotech 1Q Loss $1.93M; 15/05/2018 – Moleculin Biotech 1Q Loss/Shr 8cThe move comes after 5 months negative chart setup for the $51.28 million company. It was reported on Jun, 19 by Barchart.com. We have $1.87 PT which if reached, will make NASDAQ:MBRX worth $3.08M less.

More important recent Moleculin Biotech, Inc. (NASDAQ:MBRX) news were published by: Globenewswire.com which released: “Moleculin Invited to Present to International BioForum 2018 Conference” on May 24, 2018, also Nasdaq.com published article titled: “Moleculin Targets accelerated FDA approval of WP1732; Pursues Development for Ocular Tumors”, Nasdaq.com published: “Moleculin’s Breakthrough Discovery of a New Molecule for Cancer Treatment Advances to Development Agreement …” on June 06, 2018. More interesting news about Moleculin Biotech, Inc. (NASDAQ:MBRX) was released by: Streetinsider.com and their article: “Moleculin Biotech (MBRX) Entered Agreement with Jagiellonian University in Krakow, Poland, for Development of …” with publication date: June 12, 2018.

Moleculin Biotech, Inc., a preclinical-stage pharmaceutical company, focuses on the development of anti-cancer drug candidates. The company has market cap of $51.28 million. The Company’s lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia. It currently has negative earnings. The firm also develops other drugs, including WP1066 Portfolio that focuses on the modulation of regulatory transcription factors involved in the progression of cancer; and WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer and glioblastoma.

Analysts await Moleculin Biotech, Inc. (NASDAQ:MBRX) to report earnings on August, 13. They expect $-0.14 EPS, down 100.00% or $0.07 from last year’s $-0.07 per share. After $-0.11 actual EPS reported by Moleculin Biotech, Inc. for the previous quarter, Wall Street now forecasts 27.27% negative EPS growth.

Analysts await Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) to report earnings on August, 6. They expect $-0.10 EPS, up 28.57% or $0.04 from last year’s $-0.14 per share. After $-0.10 actual EPS reported by Idera Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

More important recent Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) news were published by: Seekingalpha.com which released: “Idera Pharma’s IMO-8400 flunks mid-stage dermatomyositis study; shares down 13% premarket” on June 12, 2018, also Seekingalpha.com published article titled: “Idera Pharmaceuticals (IDRA) ASCO Investor Event Presentation – Slideshow”, Fool.com published: “Here’s Why Idera Pharmaceuticals Fell as Much as 15.4% Today” on June 04, 2018. More interesting news about Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) was released by: Streetinsider.com and their article: “Pre-Open Movers 06/12: (GLMD) (RH) (PLAY) Higher; (IDRA) (JCAP) (IMMU) Lower (more…)” with publication date: June 12, 2018.

The stock increased 1.12% or $0.0175 during the last trading session, reaching $1.5775. About 1.04 million shares traded. Idera Pharmaceuticals, Inc. (IDRA) has risen 15.57% since June 19, 2017 and is uptrending. It has outperformed by 3.00% the S&P500. Some Historical IDRA News: ; 02/05/2018 – Idera at American Society of Clinical Oncology Meeting Jun 1; 10/04/2018 – BIOCRYST & IDERA RESCHEDULE MEETINGS TO VOTE ON PROPOSED MERGER; 24/05/2018 – IDRA, BMS PACT TO EVALUATE TLR-9 AGAINST IMO-2125 WITH YERVOY; 24/05/2018 – IDERA PHARMACEUTICALS – DEAL TO CLINICALLY EVALUATE COMBINATION OF CO’S TLR-9 AGONIST IMO-2125 WITH BMS’S THERAPY YERVOY; 01/05/2018 – Idera Pharmaceuticals Increases Operational Efficiency of Global Oncology Program with Medidata Clinical Cloud; 11/04/2018 – IDERA, BUYS WEBYOG, EXPANDING PORTFOLIO OF CROSS-PLATFORM; 07/03/2018 Idera Pharmaceuticals 4Q Loss/Shr 8c; 10/04/2018 – BioCryst and Idera Special Meetings to Be Held on July 10; 17/04/2018 – Idera Pharmaceuticals Presents Pre-Clinical Data Demonstrating Potential for Tilsotolimod (IMO-2125) in Combination with Checkp; 10/05/2018 – Invus Public Equities Advisors Buys New 1.3% Position in Idera

Since January 1, 0001, it had 0 insider buys, and 1 sale for $480,000 activity.

Baker Bros. Advisors Lp holds 0.6% of its portfolio in Idera Pharmaceuticals, Inc. for 38.64 million shares. Gmt Capital Corp owns 2.14 million shares or 0.09% of their US portfolio. Moreover, Berson & Corrado Investment Advisors Llc has 0.07% invested in the company for 61,950 shares. The Luxembourg-based Artal Group S.A. has invested 0.06% in the stock. First Midwest Bank Trust Division, a Illinois-based fund reported 246,546 shares.

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>